Reglan Tardive Dyskinesia Attorney: Statute of Limitations for Reglan in Michigan

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Understanding the Legacy of General Health Information and Reglan Risks

For decades, general health and science information has served as the foundation for public understanding of medication risks and patient safety. This broad educational context has empowered individuals to recognize potential adverse effects associated with prescription drugs, particularly those used in long-term therapy. Within this legacy framework, the focus has remained on raising awareness about the importance of informed consent and monitoring for side effects across diverse therapeutic areas. As this general health perspective evolved, it became increasingly clear that certain medications require heightened vigilance due to their potential for serious, lasting consequences. One such area of concern involves the use of Reglan (metoclopramide), a drug commonly prescribed for gastrointestinal disorders. Prolonged exposure to this medication has been linked to a condition known as tardive dyskinesia, a movement disorder that can persist even after discontinuation of the drug. This risk is particularly relevant for patients who have taken Reglan over extended periods, often without adequate warning about the cumulative nature of the danger.

Transition from General Awareness to Specific Legal Concerns in Michigan

The transition from general health education to specific occupational exposure concern arises when considering the legal and medical implications for affected individuals. In Michigan, patients who developed tardive dyskinesia after Reglan use face critical questions about the statute of limitations for filing claims. This pivot underscores the need to move beyond general awareness and toward actionable guidance for those seeking legal recourse, highlighting the intersection of medical knowledge and patient advocacy in the context of long-term medication exposure. The statute of limitations for filing a personal injury lawsuit in Michigan is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. In cases involving Reglan and TD, the timeline between exposure and documented harm is critical. Patients who developed TD after prolonged use of Reglan may need to establish when they first experienced symptoms and when they were diagnosed. The statute of limitations may begin to run from the date of diagnosis or from when the patient knew or should have known that the TD was caused by Reglan. Given that TD can develop insidiously and may be masked by the drug, patients may not immediately connect their symptoms to Reglan use. Legal counsel can help assess the specific facts of each case, including the duration of Reglan use, the onset of symptoms, and the date of diagnosis, to determine whether the claim is timely.

Medical Evidence: Reglan, Tardive Dyskinesia, and FDA Warnings

Reglan, the brand name for metoclopramide, is a medication prescribed for specific gastrointestinal conditions in adults. Its approved uses are limited to the treatment of symptomatic, documented gastroesophageal reflux for 4 to 12 weeks in adults who have not responded to conventional therapy, and for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is a serious movement disorder characterized by potentially irreversible and disfiguring involuntary movements, typically of the face or tongue, but sometimes involving the trunk and extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation can include repetitive, purposeless movements such as lip smacking, grimacing, tongue protrusion, and rapid eye blinking. Diagnosis is based on a history of exposure to a dopamine-blocking agent like metoclopramide and the presence of characteristic involuntary movements after ruling out other causes. The condition can be disfiguring and may persist even after the drug is discontinued. The mechanistic pathway linking Reglan to tardive dyskinesia involves metoclopramide's action as a dopamine receptor antagonist. By blocking dopamine receptors in the brain, particularly in the basal ganglia, the drug can disrupt normal motor control. Chronic blockade is thought to lead to upregulation of dopamine receptors and supersensitivity, which may manifest as involuntary movements. The risk of developing TD increases with the duration of metoclopramide treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA has issued a boxed warning emphasizing that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also states that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should also be avoided for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, there are concerns about the adequacy of warnings provided to patients and healthcare providers regarding the risk of TD with Reglan use. The boxed warning is present in the prescribing information, but patients may not always receive or understand this information. Additionally, the drug may be prescribed off-label or for longer durations than recommended, increasing the risk of harm. The timeline between exposure to Reglan and the development of TD can vary. Some patients may develop symptoms after months or years of use, while others may experience onset after shorter periods. The condition can also emerge after the drug is discontinued, as metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD develops, it may be irreversible, and immediate discontinuation of Reglan is recommended if signs or symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Michigan?

In Michigan, the statute of limitations for personal injury lawsuits is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For Reglan-related tardive dyskinesia, this means the clock may start from the date of diagnosis or when the patient knew or should have known that TD was caused by Reglan. Because TD can develop insidiously and may be masked by the drug, patients may not immediately connect symptoms to Reglan use. Consulting an attorney is crucial to evaluate the specific timeline.

What are the FDA warnings about Reglan and tardive dyskinesia?

The FDA has issued a boxed warning for metoclopramide (Reglan) stating that it can cause tardive dyskinesia, a potentially irreversible serious movement disorder. The warning emphasizes that Reglan should be used for the shortest duration necessary, with a maximum of 12 weeks for gastroesophageal reflux and diabetic gastroparesis. It is contraindicated in patients with a history of TD. The risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Metoclopramide Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.